Add Formweb to your mobile device
System Formulary Update
Miscellaneous Antivirals
Situation
The Miscellaneous Antivirals class review standardization was approved in July 2022.
Background
The following products were reviewed: acyclovir IV solution, acyclovir oral suspension, acyclovir capsule, acyclovir tablet, cidofovir IV solution, famciclovir tablet, foscarnet IV solution, ganciclovir IV lyophilized powder, letermovir IV solution, letermovir tablet, valacyclovir oral suspension, valacyclovir tablet, valganciclovir oral suspension, valganciclovir tablet.
Assessment/Recommendations
System P&T voted to include the following products on the UNC Health System Drug Formulary:
- Acyclovir 50 mg/mL IV solution
- Acyclovir 200 mg/5 mL oral suspension
- Acyclovir 200 mg capsule
- Cidofovir 75 mg/mL IV solution
- Foscarnet 24 mg/mL IV solution
- Ganciclovir 500 mg IV lyophilized powder
- Letermovir 480 mg/12 mL IV solution
- Letermovir 480 mg tablet
- Valacyclovir 50 mg/mL oral suspension (extemporaneous)
- Valacyclovir 500 mg tablet
- Valganciclovir 50 mg/mL oral suspension
- Valganciclovir 450 mg tablet
As a result, the following products will be removed from the inpatient drug formulary:
- Acyclovir 200 mg/5 mL (5 mL) oral suspension
- Acyclovir 400 mg tablet
- Acyclovir 800 mg tablet
- Famciclovir 125 mg tablet
- Famciclovir 500 mg tablet
- Letermovir 240 mg tablet
- Letermovir 240 mg/12 mL IV solution
- Valacyclovir 1 g tablet
Formulary/Epic changes will Go-Live on Tuesday, September 6, 2022.